Targeting kinases for the treatment of inflammatory diseases

Dual Role of the Jak1 FERM and Kinase Domains in Cytokine Receptor Binding and in Stimulation-Dependent Jak Activation

(2014) S. Haan et al.   JOURNAL OF IMMUNOLOGY

Drak2 Regulates the Survival of Activated T Cells and Is Required for Organ-Specific Autoimmune Disease

(2014) M. A. McGargill et al.   JOURNAL OF IMMUNOLOGY

Enhanced T Cell Apoptosis within Drak2-Deficient Mice Promotes Resistance to Autoimmunity

(2014) S. J. Ramos et al.   JOURNAL OF IMMUNOLOGY

Golimumab: A Tumor Necrosis Factor Alpha Inhibitor for the Treatment of Rheumatoid Arthritis

(2010) Lauren K McCluggage et al.   ANNALS OF PHARMACOTHERAPY

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Monoclonal antibodies and progressive multifocal leukoencephalopathy

(2010) Joseph R. Berger et al.   mAbs

The (un)targeted cancer kinome

(2010) Oleg Fedorov et al.   Nature Chemical Biology

Kinase inhibitors attract attention as oral rheumatoid arthritis drugs

(2010) Alisa Opar   NATURE REVIEWS DRUG DISCOVERY

Targeted therapy for systemic sclerosis: how close are we?

(2010) Manuel Ramos-Casals et al.   Nature Reviews Rheumatology

Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance

(2009) Jiarong Liu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

What have we learnt from targeted anti-TNF therapy?

(2009) M Feldmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

(2009) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies

(2009) Nemanja Damjanov et al.   ARTHRITIS AND RHEUMATISM

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

(2009) Paul W. Manley et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor Complexes

(2009) Armando G. Villaseñor et al.   Chemical Biology & Drug Design

Targeting protein kinases for the development of anti-inflammatory drugs

(2009) Philip Cohen   CURRENT OPINION IN CELL BIOLOGY

Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease

(2009) Sharmila Patel et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Therapeutic prospect of Syk inhibitors

(2009) Paolo Ruzza et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Post-transcriptional gene regulation by MAP kinases via AU-rich elements

(2009) Andrew Clark   Frontiers in Bioscience-Landmark

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Silencing Mitogen-activated Protein 4 Kinase 4 (MAP4K4) Protects Beta Cells from Tumor Necrosis Factor-α-induced Decrease of IRS-2 and Inhibition of Glucose-stimulated Insulin Secretion

(2009) Karim Bouzakri et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains

(2009) Neal K. Williams et al.   JOURNAL OF MOLECULAR BIOLOGY

Novel Tight-Binding Inhibitory Factor- B Kinase (IKK-2) Inhibitors Demonstrate Target-Specific Anti-Inflammatory Activities in Cellular Assays and following Oral and Local Delivery in an in Vivo Model of Airway Inflammation

(2009) C. D. Sommers et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

(2009) U Rix et al.   LEUKEMIA

GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38

(2009) J. Zhong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The NF-κB-independent functions of IKK subunits in immunity and cancer

(2009) Alain Chariot   TRENDS IN CELL BIOLOGY

A role for DRAK2 in the germinal center reaction and the antibody response

(2008) Ahmed Al-Qahtani et al.   AUTOIMMUNITY

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

(2008) A. Podolanczuk et al.   BLOOD

The IκB kinase – a bridge between inflammation and cancer

(2008) Michael Karin   CELL RESEARCH

ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression

(2008) Dakshina M. Jandhyala et al.   CELLULAR MICROBIOLOGY

Human tribbles homologue 2 is expressed in unstable regions of carotid plaques and regulates macrophage IL-10in vitro

(2008) Jingti Deng et al.   CLINICAL SCIENCE

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development

(2008) Monica Mita et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response

(2008) Thomas Weichhart et al.   IMMUNITY

Therapeutic targeting of Janus kinases

(2008) Marko Pesu et al.   IMMUNOLOGICAL REVIEWS

Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)

(2008) Jian-kang Jiang et al.   JOURNAL OF MEDICINAL CHEMISTRY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

(2008) Anthony J Milici et al.   ARTHRITIS RESEARCH & THERAPY

Anti-inflammatory interventions of NF-κB signaling: Potential applications and risks

(2007) Senftleben Uwe   BIOCHEMICAL PHARMACOLOGY

The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model

(2007) Hiroaki Ohno et al.   EUROPEAN JOURNAL OF IMMUNOLOGY